Your browser doesn't support javascript.
Applying context of use to quantitative polymerase chain reaction method validation and analysis: a recommendation from the European Bioanalysis Forum.
Laurén, Anna; Braun, Manuela; Byrne, Paul; Cazzin, Chiara; Colletti, Kelly; Cox, Chris; Dietz, Lisa; Emrich, Thomas; Geddes, Kristin; Herr, Kate; Iles, Tracy; Rogue, Alexandra; Verlinden, Yvan; Timmerman, Philip.
  • Laurén A; Novo Nordisk A/S, Non-Clinical & Clinical Assay Sciences, Global Discovery & Development Sciences, Global Drug Discovery, Maløv, DK-2760, Denmark.
  • Braun M; Bayer AG, DMPK Project Management, Research & Development, Pharmaceuticals, Berlin, 13342, Germany.
  • Byrne P; Labcorp Drug Development, Biopharmaceutical CMC Solutions, Harrogate, HG3 1PY, UK.
  • Cazzin C; Aptuit Srl, an Evotec Company, ADMET & Bioanalytical Sciences Dept., Campus Levi-Montalcini, Verona, 37135, Italy.
  • Colletti K; Charles River Laboratories, Laboratory Sciences, Reno, NV 89511, USA.
  • Cox C; PsiOxus Therapeutics, 4-10 The Quadrant, Abingdon, Oxfordshire, OX14 3YS, UK.
  • Dietz L; Bayer AG, DMPK Bioanalytics, Research & Development, Pharmaceuticals, Wuppertal, 42096, Germany.
  • Emrich T; F Hoffmann La Roche Pharma Research & Early Development, Pharmaceutical Sciences, Large Molecule Bioanalytical Sciences, Roche Innovation Center Munich, Penzberg, 82377, Germany.
  • Geddes K; Merck & Co, PPDM Regulated Immunogenicity, Kenilworth, NJ 07033, USA.
  • Herr K; Janssen BioTherapeutics, Janssen Research & Development LLC., Spring House, PA 19477, USA.
  • Iles T; Labcorp Drug Development, Biopharmaceutical CMC Solutions, Harrogate, HG3 1PY, UK.
  • Rogue A; Charles River Laboratories, Biomarker department, Evreux, 27000, France.
  • Verlinden Y; Janssen BioTherapeutics, JBIO Beerse Bioanalysis Laboratory, Beerse, 2340, Belgium.
  • Timmerman P; European Bioanalysis Forum, Brussels, 1000, Belgium.
Bioanalysis ; 13(23): 1723-1729, 2021 Dec.
Article in English | MEDLINE | ID: covidwho-1497587
ABSTRACT
Polymerase chain reaction (PCR) is widely used in various fields of laboratory testing, ranging from forensic, molecular biology, medical and diagnostic applications to a wide array of basic research purposes. COVID-19 infection testing has brought the three-letter PCR abbreviation into the vocabulary of billions of people, making it likely the most well-known laboratory test worldwide. With new modalities and translational medicine gaining importance in pharmaceutical research and development, PCR or more specifically, quantitative PCR (qPCR) is now becoming a standard tool in the (regulated) bioanalytical laboratory, driving the bioanalytical community to define best practices for method development, characterization and validation. In absence of specific guidance from health authorities, qPCR may be vulnerable to scope creep from pharmacokinetics (PK) assay validation as defined in bioanalytical method validation guidance/guidelines. In this manuscript, the European Bioanalysis Forum builds a rationale for applying context of use principles when defining requirements for qPCR assay performance and validation criteria.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Biological Assay / Polymerase Chain Reaction Type of study: Diagnostic study / Experimental Studies / Prognostic study / Randomized controlled trials Limits: Humans Country/Region as subject: Europa Language: English Journal: Bioanalysis Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Biological Assay / Polymerase Chain Reaction Type of study: Diagnostic study / Experimental Studies / Prognostic study / Randomized controlled trials Limits: Humans Country/Region as subject: Europa Language: English Journal: Bioanalysis Year: 2021 Document Type: Article